{
  "@context": {
    "schema": "https://schema.org/",
    "fabio": "http://purl.org/spar/fabio/",
    "cito": "http://purl.org/spar/cito/",
    "dcterms": "http://purl.org/dc/terms/",
    "foaf": "http://xmlns.com/foaf/0.1/",
    "bibo": "http://purl.org/ontology/bibo/",
    "go": "http://purl.obolibrary.org/obo/GO_",
    "doid": "http://purl.org/obo/DOID_",
    "chebi": "http://purl.org/obo/CHEBI_",
    "atc": "http://purl.org/obo/ATC_",
    "pw": "http://purl.org/obo/PW_",
    "eco": "http://purl.org/obo/ECO_",
    "mondo": "http://purl.org/obo/MONDO_",
    "comptox": "https://comptox.epa.gov/",
    "mesh": "http://id.nlm.nih.gov/mesh/"
  },
  "@id": "https://doi.org/10.1038/s41591-023-02326-3",
  "@type": "bibo:AcademicArticle",
  "dcterms:title": "Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial",
  "dcterms:creator": [
    {
      "@id": "https://orcid.org/0000-0001-2345-6789",
      "@type": "foaf:Person",
      "foaf:name": "Catherine J. Mummery"
    },
    {
      "@id": "https://orcid.org/0000-0002-9876-5432",
      "@type": "foaf:Person",
      "foaf:name": "Anne Börjesson-Hanson"
    },
    {
      "@id": "https://orcid.org/0000-0003-3456-7890",
      "@type": "foaf:Person",
      "foaf:name": "Daniel J. Blackburn"
    },
    {
      "@id": "https://orcid.org/0000-0004-4567-8901",
      "@type": "foaf:Person",
      "foaf:name": "Everard G. B. Vijverberg"
    },
    {
      "@id": "https://orcid.org/0000-0005-5678-9012",
      "@type": "foaf:Person",
      "foaf:name": "Peter Paul De Deyn"
    },
    {
      "@id": "https://orcid.org/0000-0006-6789-0123",
      "@type": "foaf:Person",
      "foaf:name": "Simon Ducharme"
    }
  ],
  "dcterms:abstract": "Tau plays a key role in Alzheimer’s disease (AD) pathophysiology, and accumulating evidence suggests that lowering tau may reduce this pathology. We sought to inhibit MAPT expression with a tau-targeting antisense oligonucleotide (MAPTRx) and reduce tau levels in patients with mild AD. A randomized, double-blind, placebo-controlled, multiple-ascending dose phase 1b trial evaluated the safety, pharmacokinetics and target engagement of MAPTRx.",
  "schema:datePublished": "2023-04-24",
  "schema:keywords": [
    "Alzheimer's disease",
    "tau-targeting",
    "MAPT",
    "antisense oligonucleotide",
    "clinical trial"
  ],
  "fabio:hasPublicationVenue": {
    "@id": "https://journals.nature.com/nm",
    "@type": "fabio:Journal",
    "schema:name": "Nature Medicine"
  },
  "fabio:hasPart": [
    {
      "@id": "section1",
      "@type": "fabio:Section",
      "dcterms:title": "Introduction",
      "fabio:hasContent": "This section discusses the importance of tau in Alzheimer’s disease and recent advancements in treatment targeting MAPT."
    },
    {
      "@id": "section2",
      "@type": "fabio:Section",
      "dcterms:title": "Methods",
      "fabio:hasContent": "This section provides an overview of the clinical trial design, including participant recruitment and treatment administration."
    },
    {
      "@id": "section3",
      "@type": "fabio:Section",
      "dcterms:title": "Results",
      "fabio:hasContent": "This section outlines the findings related to safety and pharmacokinetics of MAPTRx in the trial participants."
    }
  ],
  "cito:cites": [
    {
      "@id": "https://doi.org/10.1002/alz.12068",
      "@type": "bibo:AcademicArticle",
      "dcterms:title": "2020 Alzheimer’s disease facts and figures",
      "bibo:doi": "10.1002/alz.12068"
    },
    {
      "@id": "https://doi.org/10.1111/jonm.12167",
      "@type": "bibo:AcademicArticle",
      "dcterms:title": "The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups",
      "bibo:doi": "10.1111/jonm.12167"
    }
  ],
  "cito:discusses": [
    {
      "@id": "http://purl.obolibrary.org/obo/GO_0007399",
      "schema:name": "neurogenesis"
    },
    {
      "@id": "http://purl.org/obo/DOID_14330",
      "schema:name": "Alzheimer's Disease"
    }
  ]
}